LXRP News and Press, Lexaria Bioscience Corp. From 07/21/20

(via TheNewswire) Kelowna, British Columbia - TheNewswire - July 21, 2020 - Lexaria Bioscience Corp. (OTC:LXRP) (CSE:LXX) (CNSX:LXX.CN) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that it has filed an application with a s...

Lexaria Bioscience ( OTCQX:LXRP +11.5% ) concludes Phase 1 study of oral forms of nicotine delivery, utilizing its DehydraTECH  technology. The study evaluated reduced health risks relative to combusted tobacco of a preliminary DehydraTECH oral nicotine formulation. More news...

R&D Program Utilized Lexaria's Patented DehydraTECH TM Technology for Oral Nicotine Delivery Conclusion of Phase I allows for additional phased private financings up to a further US$11 million from Altria KELOWNA, BC / ACCESSWIRE / July 16, 2020 / Lexaria Bioscience Corp. (O...

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) , a global innovator in drug delivery platforms, on Monday announced it has retained IRTH Communications, LLC ("IRTH") to provide investor relations and communications services to the Company in compliance with regulatory guidelines. According...

(via TheNewswire) KELOWNA, BC - TheNewswire - June 29, 2020 - Lexaria Bioscience Corp. (OTC: LXRP ) (CSE: LXX ) (CNSX:LXX.CN) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announced it has retained IRTH Communications, LLC ("IR...

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) , a global innovator in drug delivery platforms, today announced the results of the 2020 Annual and Special Meeting (the "Meeting"). According to the update, the Meeting was held at 1:00 p.m. (Pacific Time) on June 23, 2020, whereby there were...

(via TheNewswire) Kelowna, British Columbia - TheNewswire - June 24, 2020 - Lexaria Bioscience Corp. (OTC:LXRP) (CSE:LXX) (CNSX:LXX.CN) (the "Company" or "Lexaria") announces the results of the 2020 Annual and Special Meeting (the "Meeting"). On June 23, 2020...

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) , a global innovator in drug delivery platforms, today announced its submission of a grant application to the U.S. National Institutes of Health (“NIH”) entitled "In vitro and in vivo animal exploratory pharmacokinetic and prelim...

(via TheNewswire) KELOWNA, BC - TheNewswire - June 18, 2020 - Lexaria Bioscience Corp. (OTC: LXRP ) (CSE: LXX ) (CNSX:LXX.CN) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces it has submitted a grant application to the...

(via TheNewswire) KELOWNA, BC - TheNewswire - June 4, 2020 - Christopher Bunka, Chief Executive Officer and director of Lexaria Bioscience Corp. (the " Company "), (CNSX:LXX.CN) of 100 - 740 McCurdy Road, Kelowna, BC V1X 2P7, announces his intention to file an ear...